A Two Arm Safety Study of Regorafenib Before or After SIR-Spheres Microspheres (90Y) for the Treatment of Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 May 2017
At a glance
- Drugs Regorafenib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions
- 04 May 2017 Status changed from recruiting to active, no longer recruiting.
- 24 Jan 2017 Planned End Date changed from 1 Dec 2017 to 1 Jan 2018.
- 24 Jan 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Oct 2017.